(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.
Fig. 1. SB203580 and SP600125 inhibit normal blastocoel formation. (A) Schedule of
inhibitor treatment and analysis of preimplantation embryos. The program of
developmental processes is shown at the top. Arrowheads indicate timing of
compaction and that of cavitation. Bars in scheme 1, 2, 3 and 4 indicate the
duration of the inhibitor treatment. At the end of the bars (indicated by
arrowheads), embryos were observed and the typical images are shown in B. The
zona pellucida was removed before the inhibitor was added to M16 medium. The
inhibitor was added at the early eight-cell stage, and embryos were examined
before the cavitation in scheme 1. In scheme 2, the inhibitor was added at the
early eight-cell stage, and embryos were examined at the blastocyst stage. In
scheme 3, the inhibitor was added at the pre-cavitation stage. In scheme 4,
the inhibitor was added after initiation of cavitation. (B) Schematic
representation of the phenotypes of embryos treated with each inhibitor. (C)
Embryos treated with 20 µM SB203580 (+SB) or 25 µM SP600125 (+SP) were
compared with control embryos (Cont.). 1, 2, 3 and 4 correspond to those in A.
(D) Time-dependent observations of control, SB203580-treated or
SP600125-treated embryos were performed. The inhibitor (SB or SP) was added at
the eight-cell stage.
